357 related articles for article (PubMed ID: 19491205)
1. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation.
Kolve H; Ahlke E; Fegeler W; Ritter J; Jürgens H; Groll AH
J Antimicrob Chemother; 2009 Aug; 64(2):383-7. PubMed ID: 19491205
[TBL] [Abstract][Full Text] [Related]
2. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients.
Allinson K; Kolve H; Gumbinger HG; Vormoor HJ; Ehlert K; Groll AH
J Antimicrob Chemother; 2008 Mar; 61(3):734-42. PubMed ID: 18238891
[TBL] [Abstract][Full Text] [Related]
3. Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients.
Bochennek K; Tramsen L; Schedler N; Becker M; Klingebiel T; Groll AH; Lehrnbecher T
Clin Microbiol Infect; 2011 Dec; 17(12):1868-74. PubMed ID: 21895857
[TBL] [Abstract][Full Text] [Related]
4. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.
Alexander BD; Dodds Ashley ES; Addison RM; Alspaugh JA; Chao NJ; Perfect JR
Transpl Infect Dis; 2006 Mar; 8(1):13-20. PubMed ID: 16623816
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
[TBL] [Abstract][Full Text] [Related]
6. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation.
Roman E; Osunkwo I; Militano O; Cooney E; van de Ven C; Cairo MS
Pediatr Blood Cancer; 2008 Feb; 50(2):325-30. PubMed ID: 17514732
[TBL] [Abstract][Full Text] [Related]
7. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.
El-Cheikh J; Faucher C; Fürst S; Duran S; Berger P; Vey N; Stoppa AM; Bouabdallah R; Gastaut JA; Viens P; Blaise D; Mohty M
Bone Marrow Transplant; 2007 Mar; 39(5):301-6. PubMed ID: 17262059
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation.
Ringdén O; Andström EE; Remberger M; Dahllöf G; Svahn BM; Tollemar J
Pediatr Transplant; 1997 Nov; 1(2):124-9. PubMed ID: 10084772
[TBL] [Abstract][Full Text] [Related]
9. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
10. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey.
Groll AH; Attarbaschi A; Schuster FR; Herzog N; Grigull L; Dworzak MN; Beutel K; Laws HJ; Lehrnbecher T
J Antimicrob Chemother; 2006 Mar; 57(3):527-35. PubMed ID: 16431856
[TBL] [Abstract][Full Text] [Related]
11. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies.
Mehta J; Kelsey S; Chu P; Powles R; Hazel D; Riley U; Evans C; Newland A; Treleaven J; Singhal S
Bone Marrow Transplant; 1997 Jul; 20(1):39-43. PubMed ID: 9232254
[TBL] [Abstract][Full Text] [Related]
13. Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study.
Morello E; Pagani L; Coser P; Cavattoni I; Cortelazzo S; Casini M; Billio A; Rossi G
Bone Marrow Transplant; 2011 Jan; 46(1):132-6. PubMed ID: 20383205
[TBL] [Abstract][Full Text] [Related]
14. Treatment of mycotic infections after haemopoietic progenitor cell transplantation with liposomal amphotericin-B.
Krüger WH; Kröger N; Rüssmann B; Renges H; Kabisch H; Zander AR
Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S10-3. PubMed ID: 9916623
[TBL] [Abstract][Full Text] [Related]
15. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
[TBL] [Abstract][Full Text] [Related]
16. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT.
Hebart H; Klingspor L; Klingebiel T; Loeffler J; Tollemar J; Ljungman P; Wandt H; Schaefer-Eckart K; Dornbusch HJ; Meisner C; Engel C; Stenger N; Mayer T; Ringden O; Einsele H
Bone Marrow Transplant; 2009 Apr; 43(7):553-61. PubMed ID: 19079316
[TBL] [Abstract][Full Text] [Related]
17. Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy.
Grigull L; Kuehlke O; Beilken A; Sander A; Linderkamp C; Schmid H; Seidemann K; Sykora KW; Schuster FR; Welte K
Pediatr Transplant; 2007 May; 11(3):261-6. PubMed ID: 17430480
[TBL] [Abstract][Full Text] [Related]
18. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease.
Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Dellow E; Herbrecht R; Donnelly JP
Mycoses; 2011 Sep; 54(5):e449-55. PubMed ID: 21039936
[TBL] [Abstract][Full Text] [Related]
19. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
20. The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation.
Safdar A; Rodriguez G; Ohmagari N; Kontoyiannis DP; Rolston KV; Raad II; Champlin RE
Cancer; 2005 Feb; 103(4):731-9. PubMed ID: 15641032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
